

Claudia De Lorenzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5360932/publications.pdf>

Version: 2024-02-01

69
papers

1,924
citations

172457

29
h-index

289244

40
g-index

69
all docs

69
docs citations

69
times ranked

2039
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand. <i>Cancers</i> , 2022, 14, 1325.	3.7	14
2	Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3466.	4.1	6
3	Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC. <i>Cancers</i> , 2022, 14, 121.	3.7	7
4	A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5556.	4.1	3
5	Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, Galectine-3 and NLRP3-MyD88-chemokine pathways.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14516-e14516.	1.6	0
6	Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 11046.	3.3	13
7	Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. <i>Cancers</i> , 2021, 13, 2858.	3.7	12
8	Long-chain polyphosphates impair SARS-CoV-2 infection and replication. <i>Science Signaling</i> , 2021, 14, .	3.6	27
9	Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8562.	4.1	20
10	Differential cardiotoxicity of immune checkpoint inhibitors involves dampens fibronectin-EDA, calgranulin, galectine-3, and associated nlrp3 inflammasome-interleukins pathway in preclinical models. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
11	Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells. <i>Cancers</i> , 2020, 12, 2204.	3.7	12
12	Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. <i>Journal of Personalized Medicine</i> , 2020, 10, 179.	2.5	41
13	Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 180.	8.6	38
14	Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. <i>Cancers</i> , 2020, 12, 331.	3.7	27
15	Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing. <i>Cancers</i> , 2019, 11, 1268.	3.7	38
16	Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling. <i>Scientific Reports</i> , 2019, 9, 13125.	3.3	44
17	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. <i>International Journal of Cardiology</i> , 2019, 292, 171-179.	1.7	44
18	T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. <i>Journal of Immunotherapy</i> , 2019, 42, 1-10.	2.4	11

#	ARTICLE	IF	CITATIONS
19	Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. <i>BioMed Research International</i> , 2019, 2019, 1-22.	1.9	9
20	A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells. <i>MAbs</i> , 2018, 10, 730-737.	5.2	25
21	Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. <i>Frontiers in Physiology</i> , 2018, 9, 38.	2.8	36
22	Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. <i>MAbs</i> , 2018, 10, 1-13.	5.2	31
23	Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2241-2250.	2.0	26
24	Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody. <i>Journal of Immunotherapy</i> , 2017, 40, 117-128.	2.4	7
25	Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6785-6794.	2.0	24
26	Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e19-e26.	1.5	47
27	A Practical Approach for Management of QT Prolongation Induced by Anticancer Drugs. <i>Oncologist</i> , 2016, , .	3.7	1
28	Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1124-1131.	3.3	46
29	Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. <i>Journal of General Virology</i> , 2016, 97, 82-94.	2.9	16
30	A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy. <i>Oncotarget</i> , 2016, 7, 87016-87030.	1.8	23
31	One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	16
32	Human anti-nucleolin recombinant immunoagent for cancer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9418-9423.	7.1	53
33	Effect of ranolazine administered after trastuzumab treatment on cardiotoxicity in mice.. <i>Journal of Clinical Oncology</i> , 2015, 33, 597-597.	1.6	0
34	Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation. <i>Journal of Biological Chemistry</i> , 2014, 289, 35015-35028.	3.4	17
35	Effects of a human compact anti-ErbB2 antibody on gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 107-115.	5.3	6
36	Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. <i>European Journal of Heart Failure</i> , 2014, 16, 358-366.	7.1	76

#	ARTICLE	IF	CITATIONS
37	Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. <i>Protein Engineering, Design and Selection</i> , 2014, 27, 83-88.	2.1	16
38	Ranolazine and prevention of trastuzumab-cardiotoxicity in experimental models.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13508-e13508.	1.6	0
39	A novel fully human antitumor ImmunoRNase resistant to the RNase inhibitor. <i>Protein Engineering, Design and Selection</i> , 2013, 26, 243-248.	2.1	17
40	Effects of a human compact anti-ErbB2 antibody on prostate cancer. <i>Oncology Reports</i> , 2012, 28, 297-302.	2.6	3
41	Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. <i>European Journal of Heart Failure</i> , 2012, 14, 130-137.	7.1	77
42	Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 595-602.	2.5	56
43	Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 511-521.	2.5	43
44	A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. <i>British Journal of Cancer</i> , 2011, 104, 1716-1723.	6.4	35
45	A novel ErbB2 epitope targeted by human antitumor immunoagents. <i>FEBS Journal</i> , 2011, 278, 1156-1166.	4.7	12
46	Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. <i>British Journal of Cancer</i> , 2010, 102, 513-519.	6.4	29
47	Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. <i>FASEB Journal</i> , 2009, 23, 3171-3178.	0.5	63
48	Human anti-ErbB2 immunoagents as immunoRNases and compact antibodies. <i>FEBS Journal</i> , 2009, 276, 1527-1535.	4.7	19
49	Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. <i>FEBS Journal</i> , 2008, 275, 4967-4979.	4.7	33
50	A Novel Human Antitumor Dimeric ImmunoRNase. <i>Journal of Immunotherapy</i> , 2008, 31, 440-445.	2.4	13
51	From ImmunoToxins to ImmunoRNases. <i>Current Pharmaceutical Biotechnology</i> , 2008, 9, 210-214.	1.6	38
52	Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin. <i>British Journal of Cancer</i> , 2007, 97, 1354-1360.	6.4	11
53	Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. <i>FEBS Letters</i> , 2007, 581, 296-300.	2.8	31
54	Biological properties of a human compact anti-ErbB2 antibody. <i>Carcinogenesis</i> , 2005, 26, 1890-1895.	2.8	37

#	ARTICLE	IF	CITATIONS
55	A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. <i>British Journal of Cancer</i> , 2004, 91, 1200-1204.	6.4	41
56	A Fully Human Antitumor ImmunoRNase Selective for ErbB-2-Positive Carcinomas. <i>Cancer Research</i> , 2004, 64, 4870-4874.	0.9	67
57	Crystal structure of the dimeric unswapped form of bovine seminal ribonuclease. <i>FEBS Letters</i> , 2003, 554, 105-110.	2.8	25
58	A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. <i>FEBS Letters</i> , 2002, 516, 208-212.	2.8	32
59	A new human antitumor immunoreagent specific for ErbB2. <i>Clinical Cancer Research</i> , 2002, 8, 1710-9.	7.0	46
60	The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane. <i>Oncogene</i> , 2001, 20, 599-608.	5.9	57
61	Trypsin Sheds Light on the Singular Case of Seminal RNase, a Dimer with Two Quaternary Conformations. <i>Journal of Biological Chemistry</i> , 2000, 275, 8000-8006.	3.4	10
62	Thermodynamic Stability of the Two Isoforms of Bovine Seminal Ribonuclease. <i>Biochemistry</i> , 2000, 39, 7964-7972.	2.5	11
63	A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 7768-7773.	7.1	66
64	Crystallization of multiple forms of bovine seminal ribonuclease in the liganded and unliganded state. <i>Journal of Crystal Growth</i> , 1999, 196, 305-312.	1.5	9
65	Selective and asymmetric action of trypsin on the dimeric forms of seminal RNase. <i>Protein Science</i> , 1998, 7, 2653-2658.	7.6	6
66	Effects of Protein RNase Inhibitor and Substrate on the Quaternary Structures of Bovine Seminal RNase. <i>Biochemistry</i> , 1996, 35, 3880-3885.	2.5	39
67	A Study of the Intracellular Routing of Cytotoxic Ribonucleases. <i>Journal of Biological Chemistry</i> , 1995, 270, 17476-17481.	3.4	86
68	The antitumor action of seminal ribonuclease and its quaternary conformations. <i>FEBS Letters</i> , 1995, 359, 31-34.	2.8	71
69	Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	9